Abstract | BACKGROUND: PROCEDURE: In the ALL92 MT study we prospectively registered the intake of MTX/6MP. The registration was done when blood samples for erythrocyte MTX/6MP metabolite measurements were collected, and referred to the time of intake in the period since last registration. Nine thousand one hundred ninety-five registrations in total. The administration of MTX/6MP was scored as morning, midday, or evening. RESULTS: Of 532 patients, 296 took their medication consistently in the evening, 129 in the evening 50.0-99.9% of the time, and 101 in the evening <50% of the time, six did not have any registrations. The circadian schedule did not differ significantly by age, sex, MTX/6MP doses, and average absolute neutrophil counts. The circadian schedule groups did differ on risk groups (P = 0.003) with fewer HR patients in the 50-99.9% group, and there was a negative correlation between percentage of time on evening schedule and average WBC (Spearman's rho -0.15; P = 0.0004). Average WBC was not associated with relapse on ALL92. In a Cox multivariate model the circadian schedule of MTX/6MP was not of prognostic significance for the risk of relapse, and the 10-year cumulative relapse risk was below 20% in all groups. CONCLUSION: An evening schedule may still be recommended based on the previous publications, but in this study morning administration of MTX and 6MP does not seem to impact EFS.
|
Authors | Kim K B Clemmensen, Regitse H Christensen, Diana N Shabaneh, Arja Harila-Saari, Mats Heyman, Olafur G Jonsson, Finn Wesenberg, Susanne Rosthøj, Kjeld Schmiegelow, Nordic Society of Pediatric Hematology, Oncology (NOPHO) |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 61
Issue 4
Pg. 653-8
(Apr 2014)
ISSN: 1545-5017 [Electronic] United States |
PMID | 24265159
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2013 Wiley Periodicals, Inc. |
Chemical References |
- Mercaptopurine
- Methotrexate
|
Topics |
- Administration, Oral
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Child
- Child, Preschool
- Circadian Rhythm
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Infant
- Male
- Mercaptopurine
(administration & dosage)
- Methotrexate
(administration & dosage)
- Neoplasm Recurrence, Local
(drug therapy, mortality, pathology)
- Neoplasm Staging
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy, mortality, pathology)
- Prognosis
- Prospective Studies
- Survival Rate
|